

Robert M Califf

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7291347/robert-m-califf-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

19,956
citations

62
h-index

140
g-index

257
ext. papers

23,520
ext. citations

11.9
avg, IF

6.74
L-index

#	Paper	IF	Citations
218	Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study.. <i>BMJ Open</i> , 2022 , 12, e054741	3	0
217	The Ecosystem to Support People with Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	2
216	A call to action for new global approaches to cardiovascular disease drug solutions. <i>European Heart Journal</i> , 2021 , 42, 1464-1475	9.5	16
215	Avoiding the Coming Tsunami of Common, Chronic Disease: What the Lessons of the COVID-19 Pandemic Can Teach Us. <i>Circulation</i> , 2021 , 143, 1831-1834	16.7	3
214	Mapping and quantification of the twitter footprint of cardiologists. <i>European Heart Journal Digital Health</i> , 2021 , 2, 374-378	2.3	2
213	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. <i>Circulation</i> , 2021 , 144, 159-169	16.7	8
212	Return of individual research results: What do participants prefer and expect?. <i>PLoS ONE</i> , 2021 , 16, e0254753	5.7	1
211	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	3
210	A holistic approach for suppression of COVID-19 spread in workplaces and universities. <i>PLoS ONE</i> , 2021 , 16, e0254798	3.7	3
209	Toward a Mobile Platform for Real-world Digital Measurement of Depression: User-Centered Design, Data Quality, and Behavioral and Clinical Modeling. <i>JMIR Mental Health</i> , 2021 , 8, e27589	6	2
208	Importance of Social Determinants in Screening for Depression. <i>Journal of General Internal Medicine</i> , 2021 , 1	4	2
207	Life expectancy and voting patterns in the 2020 U.S. presidential election. <i>SSM - Population Health</i> , 2021 , 15, 100840	3.8	0
206	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e022485	6	
205	Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1852-1854	27.4	39
204	Reimagining What We Measure in Atherosclerosis-a "Phenotype Stack". <i>Circulation Research</i> , 2020 , 126, 1146-1158	15.7	2
203	The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020 , 3, 84	15.7	10
202	Precision Health Analytics With Predictive Analytics and Implementation Research: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 306-320	15.1	7

201	Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. <i>Circulation</i> , 2020 , 141, e615-e644	16.7	63
200	Big Data in the Assessment of Pediatric Medication Safety. <i>Pediatrics</i> , 2020 , 145,	7.4	3
199	Understanding the use of observational and randomized data in cardiovascular medicine. <i>European Heart Journal</i> , 2020 , 41, 2571-2578	9.5	13
198	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. <i>American Heart Journal</i> , 2020 , 226, 4-12	4.9	2
197	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. <i>Contemporary Clinical Trials</i> , 2020 , 88, 105775	2.3	4
196	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020 , 3, e2014661	10.4	1
195	Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative [®] Partnering With Regulators Learning Collaborative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006606	5.8	7
194	Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 580-589	15.1	22
193	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. <i>Diabetes Care</i> , 2020 , 43, 2485-2492	14.6	2
192	Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation. <i>Circulation</i> , 2019 , 140, 1426-1436	16.7	30
191	High-quality evidence to inform clinical practice. <i>Lancet, The</i> , 2019 , 394, 633-634	40	5
190	Consequences of Slow Progress Toward Pragmatism in Randomized Clinical Trials: It Is Time to Get Practical. <i>JAMA Cardiology</i> , 2019 , 4, 1129-1130	16.2	2
189	Proposals to Lower Medication Costs-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 982-983	27.4	
188	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019 , 218, 110-122	4.9	7
187	Employ Cybersecurity Techniques Against the Threat of Medical Misinformation. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 207-208	27.4	1
186	Consent for Research Participation in Practice. <i>American Journal of Bioethics</i> , 2019 , 19, 19-21	1.1	
185	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1069-1080	27.4	79
184	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1057-1068	15.1	21

183	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 846-854	16.2	40
182	Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. <i>JACC: Heart Failure</i> , 2019 , 7, 980-992	7.9	11
181	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. <i>PLoS ONE</i> , 2019 , 14, e0219894	3.7	2
180	Facilitating translational team science: The project leader model. <i>Journal of Clinical and Translational Science</i> , 2019 , 3, 140-146	0.4	4
179	Balanced Dysfunction in the Healthcare Ecosystem Harms Patients. <i>Circulation</i> , 2019 , 140, 1860-1864	16.7	1
178	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	16.7	8
177	Differences in Health Outcomes between Men and Women: Biological, Behavioral, and Societal Factors. <i>Clinical Chemistry</i> , 2019 , 65, 19-23	5.5	5
176	Improving Clinical Outcomes in the Era of Information Ubiquity. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 7-12	12.7	
175	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005041	5.8	8
174	Stroke prevention in atrial fibrillation: re-defining real-world data within the broader data universe. <i>European Heart Journal</i> , 2018 , 39, 2932-2941	9.5	19
173	Biomarker definitions and their applications. <i>Experimental Biology and Medicine</i> , 2018 , 243, 213-221	3.7	299
172	Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 443-453	15.1	22
171	Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2018 , 6, 619-632	7.9	72
170	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018 , 122, 1451-1458	3	1
169	Individual risk prediction using data beyond the medical clinic. <i>Cmaj</i> , 2018 , 190, E947-E948	3.5	3
168	The future of humans as model organisms. <i>Science</i> , 2018 , 361, 552-553	33.3	19
167	Transforming Psychiatry into Data-Driven Medicine with Digital Measurement Tools. <i>Npj Digital Medicine</i> , 2018 , 1, 37	15.7	30
166	Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full. <i>Clinical Trials</i> , 2018 , 15, 235-239	2.2	3

165	Return of Research Results to Study Participants: Uncharted and Untested. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 435-436	27.4	37
164	Comparison of Observational Data and the ONTARGET Results for Telmisartan Treatment of Hypertension: Bullseye or Painting the Target Around the Arrow?. <i>JAMA Internal Medicine</i> , 2018 , 178, 63-65	11.5	3
163	Providing Individual Research Results to Participants-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2601	27.4	2
162	Future of Personalized Cardiovascular Medicine: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3301-3309	15.1	17
161	Work and Cardiovascular Disease in China. <i>JAMA Network Open</i> , 2018 , 1, e184815	10.4	
160	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004783	5.8	7
159	Large Clinical Trials and Registries Clinical Research Institutes 2018 , 411-444		
158	Accelerating development of scientific evidence for medical products within the existing US regulatory framework. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 297-298	64.1	38
157	Evaluating Evolving Technologies in a Time of Rapid Change: The Case of Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2017 , 2, 830-831	16.2	1
156	Cosmetics, Regulations, and the Public Health: Understanding the Safety of Medical and Other Products. <i>JAMA Internal Medicine</i> , 2017 , 177, 1080-1082	11.5	13
155	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016 , 1, 93-100	5.6	
154	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016 , 171, 25-32	4.9	10
153	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016 , 102, 1036-43	5.1	30
152	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016 , 5, e002197	6	94
151	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 389-97	9.4	8
150	Pragmatic clinical trials: Emerging challenges and new roles for statisticians. <i>Clinical Trials</i> , 2016 , 13, 471-2	12	15
149	Transforming Evidence Generation to Support Health and Health Care Decisions. <i>New England Journal of Medicine</i> , 2016 , 375, 2395-2400	59.2	88
148	Compliance with results reporting at ClinicalTrials.gov. <i>New England Journal of Medicine</i> , 2015 , 372, 1031-2	59.2	243

147	The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015 , 169, 743-50	4.9	14
146	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. <i>American Heart Journal</i> , 2015 , 170, 117-22	4.9	25
145	Cardiovascular drug development: is it dead or just hibernating?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1567-82	15.1	104
144	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet</i> , 2015 , 387, 862-70	4.0	100
143	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015 , 170, 290-7	4.9	41
142	Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization. <i>Circulation: Heart Failure</i> , 2015 , 8, 473-80	7.6	46
141	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>JACC: Heart Failure</i> , 2015 , 3, 777-85	7.9	18
140	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial. <i>American Heart Journal</i> , 2015 , 169, 175-84	4.9	16
139	Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. <i>American Journal of Medicine</i> , 2015 , 128, 297-302	2.4	6
138	Exploring the ethical and regulatory issues in pragmatic clinical trials. <i>Clinical Trials</i> , 2015 , 12, 436-41	2.2	117
137	Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 168-77		15
136	Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems. <i>Clinical Trials</i> , 2015 , 12, 276-86	2.2	41
135	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015 , 36, 288-96	9.5	203
134	CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. <i>Clinical and Translational Science</i> , 2015 , 8, 623-31	4.9	2
133	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. <i>BMJ Open</i> , 2015 , 5, e007901	3	6
132	Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. <i>Journal of the American Heart Association</i> , 2015 , 4, e001349	6	6
131	Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. <i>JACC: Heart Failure</i> , 2015 , 3, 40-49	7.9	31
130	Methods and initial findings from the Durham Diabetes Coalition: Integrating geospatial health technology and community interventions to reduce death and disability. <i>Journal of Clinical and Translational Endocrinology</i> , 2015 , 2, 26-36	2.4	19

129	Translation of acute coronary syndrome therapies: from evidence to routine clinical practice. <i>American Heart Journal</i> , 2015 , 169, 266-73	4.9	13
128	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014 , 35, 1873-80	9.5	126
127	Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). <i>JACC: Heart Failure</i> , 2014 , 2, 159-65	7.9	65
126	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , 2014 , 383, 1059-66	4.0	143
125	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 891-900	15.1	172
124	Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014 , 177, 840-6	3.2	9
123	Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014 , 176, 1126-8	3.2	8
122	Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. <i>Circulation</i> , 2014 , 130, 1445-51	16.7	138
121	Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. <i>Stroke</i> , 2014 , 45, 1739-47	6.7	106
120	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--AuthorsPreply. <i>Lancet, The</i> , 2014 , 384, 1097-8	4.0	4
119	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet, The</i> , 2014 , 383, 2008-17	4.0	167
118	Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014 , 129, 1230-40	16.7	281
117	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 554-61	12.7	27
116	The Patient-Centered Outcomes Research Network: a national infrastructure for comparative effectiveness research. <i>North Carolina Medical Journal</i> , 2014 , 75, 204-10	0.6	29
115	Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. <i>Circulation: Heart Failure</i> , 2014 , 7, 918-25	7.6	37
114	Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). <i>Circulation</i> , 2014 , 130, 958-65	16.7	36
113	Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 828-34	5.8	26
112	Large simple trials: really, it can be that simple!. <i>European Heart Journal</i> , 2014 , 35, 549-51	9.5	5

111	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014 , 35, 3377-85	9.5	127
110	Launching PCORnet, a national patient-centered clinical research network. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014 , 21, 578-82	8.6	331
109	Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. <i>Circulation</i> , 2014 , 130, 1812-9	16.7	31
108	Ethics and regulatory complexities for pragmatic clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2381-2	27.4	99
107	Commentary on Vickers. <i>Clinical Trials</i> , 2014 , 11, 626-7	2.2	2
106	Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. <i>JAMA Surgery</i> , 2014 , 149, 798-805	5.4	52
105	High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , 2014 , 20, 319-26	3.3	37
104	The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. <i>American Journal of Kidney Diseases</i> , 2014 , 63, 771-80	7.4	86
103	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014 , 11, 925-32	6.7	43
102	Independent data monitoring committees: preparing a path for the future. <i>American Heart Journal</i> , 2014 , 168, 135-41.e1	4.9	14
101	Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. <i>American Heart Journal</i> , 2014 , 168, 213-9.e1	4.9	44
100	Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. <i>American Heart Journal</i> , 2014 , 167, 921-9.e2	4.9	21
99	Rescuing clinical trials in the United States and beyond: a call for action. <i>American Heart Journal</i> , 2013 , 165, 837-47	4.9	40
98	Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 651-8	15.1	159
97	Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013 , 1, 523-30	7.9	19
96	Forging stronger partnerships between academic health centers and patient-driven organizations. <i>Academic Medicine</i> , 2013 , 88, 1220-4	3.9	14
95	Randomized clinical trials--removing unnecessary obstacles. <i>New England Journal of Medicine</i> , 2013 , 369, 1061-5	59.2	78
94	Assessing research results in the medical literature: trust but verify. <i>JAMA Internal Medicine</i> , 2013 , 173, 1053-5	11.5	4

93	Geographic health information systems: a platform to support the triple aim? <i>Health Affairs</i> , 2013 , 32, 1608-15	7	57
92	Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.gov. <i>Journal of the American Heart Association</i> , 2013 , 2, e000009	6	11
91	Cycle Time Metrics for Multisite Clinical Trials in the United States. <i>Therapeutic Innovation and Regulatory Science</i> , 2013 , 47, 152-160	1.2	9
90	Embedding cardiovascular research into practice. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2037-8	27.4	28
89	A comparison of phenotype definitions for diabetes mellitus. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013 , 20, e319-26	8.6	74
88	Rationale for key elements of Sino-American collaboration in clinical research. <i>Journal of Translational Medicine</i> , 2012 , 10,	8.5	78
87	Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1838-47	27.4	301
86	The future of cardiovascular clinical research: informatics, clinical investigators, and community engagement. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1747-8	27.4	19
85	Establishing a framework for improving the quality of clinical and translational research. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1725-6	2.2	4
84	Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Stroke</i> , 2012 , 43,	6.7	3
83	Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 883-91	59.2	6302
82	The ClinicalTrials.gov results database--update and key issues. <i>New England Journal of Medicine</i> , 2011 , 364, 852-60	59.2	465
81	A historical perspective on clinical trials innovation and leadership: where have the academics gone?. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 713-4	27.4	41
80	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, SB Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 242-66	5.1	2
79	Commentary on Anand et al. <i>Clinical Trials</i> , 2011 , 8, 724-5; discussion 726	2.2	
78	Towards a new order in cardiovascular medicine: re-engineering through global collaboration. <i>European Heart Journal</i> , 2010 , 31, 911-7	9.5	6
77	Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium. <i>Academic Medicine</i> , 2010 , 85, 463-9	3.9	56
76	Linking scientific discovery and better health for the nation: the first three years of the NIH Clinical and Translational Science Awards. <i>Academic Medicine</i> , 2010 , 85, 457-62	3.9	41

75	Careers for clinician investigators. <i>Circulation</i> , 2009 , 119, 2945-50	16.7	8
74	Scientific evidence underlying the ACC/AHA clinical practice guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 831-41	27.4	55 ⁸
73	Rational use of medications: if Canada can do it. <i>Cmaj</i> , 2009 , 181, 15-6	3.5	3
72	Clinical research sites--the underappreciated component of the clinical research system. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 2025-7	27.4	28
71	Traversing the valley of death: a guide to assessing prospects for translational success. <i>Science Translational Medicine</i> , 2009 , 1, 10cm9	17.5	63
70	Ethical and scientific implications of the globalization of clinical research. <i>New England Journal of Medicine</i> , 2009 , 360, 816-23	59.2	494
69	Key issues for global cardiovascular medicine. <i>Lancet, The</i> , 2009 , 374, 508-10	4.0	5
68	Sensible approaches for reducing clinical trial costs. <i>Clinical Trials</i> , 2008 , 5, 75-84	2.2	119
67	Considerations of net present value in policy making regarding diagnostic and therapeutic technologies. <i>American Heart Journal</i> , 2008 , 156, 879-85	4.9	10
66	Rationale and design of IMPROVE-IT (IMPROved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2008 , 156, 826-32	4.9	24 ⁰
65	Organizational improvements to enhance modern clinical epidemiology. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 2300-2	27.4	11
64	Sensible guidelines for the conduct of large randomized trials. <i>Clinical Trials</i> , 2008 , 5, 38-9	2.2	43
63	Analyses of cancer data from three ezetimibe trials. <i>New England Journal of Medicine</i> , 2008 , 359, 1357-66	59.2	190
62	The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. <i>Pharmacoepidemiology and Drug Safety</i> , 2008 , 17, 782-6	2.6	2
61	Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 5-16	2.6	14
60	Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. <i>Health Affairs</i> , 2007 , 26, 62-74	7	23
59	Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products?. <i>Drug Information Journal</i> , 2007 , 41, 491-499		1
58	Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. <i>Archives of Internal Medicine</i> , 2006 , 166, 2027-34		13 ⁰

57	Clinical trials bureaucracy: unintended consequences of well-intentioned policy. <i>Clinical Trials</i> , 2006 , 3, 496-502	2.2	59
56	Translating clinical trials into practice. <i>Texas Heart Institute Journal</i> , 2006 , 33, 192-6	0.8	2
55	A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2005 , 149, S91-9	4.9	9
54	Prognostic/Clinical Prediction Models: Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry 2005 , 287-314		
53	Defining the balance of risk and benefit in the era of genomics and proteomics. <i>Health Affairs</i> , 2004 , 23, 77-87	0	21
52	Benefit the patient, manage the risk: a system goal. <i>Pharmacoepidemiology and Drug Safety</i> , 2004 , 13, 269-76	2.6	1
51	A time of accelerated change in academic cardiovascular medicine: implications for academic divisions of cardiology and their training programs. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1957-65	15.1	1
50	Task Force 2: Investigator Participation in Clinical Research. <i>Circulation</i> , 2004 , 110, 2517-2524	16.7	1
49	Red Blood Cell S-Nitrosohemoglobin Deficiency in Pulmonary Arterial Hypertension.. <i>Blood</i> , 2004 , 104, 1583-1583	2.2	
48	Toward protecting the safety of participants in clinical trials. <i>Contemporary Clinical Trials</i> , 2003 , 24, 256-71		51
47	Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?. <i>Statistics in Medicine</i> , 2002 , 21, 2889-97	2.3	1
46	Introduction: Redefining acute coronary syndrome care in the era of aggressive revascularization. <i>Clinical Cardiology</i> , 2002 , 25, 1-1	3.3	78
45	Matching resources to treatment decisions for patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2002 , 25, 12-8	3.3	1
44	Principles from clinical trials relevant to clinical practice: Part II. <i>Circulation</i> , 2002 , 106, 1172-5	16.7	30
43	Principles from clinical trials relevant to clinical practice: Part I. <i>Circulation</i> , 2002 , 106, 1015-21	16.7	78
42	Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). <i>Circulation</i> , 2002 , 106, 920-6	16.7	493
41	Integrating quality into the cycle of therapeutic development. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1895-901	15.1	105
40	Using observational data to estimate prognosis: an example using a coronary artery disease registry. <i>Statistics in Medicine</i> , 2001 , 20, 2505-32	2.3	19

39	Statistical approaches and policies for the operations of Data and Safety Monitoring Committees. <i>American Heart Journal</i> , 2001 , 141, 301-5	4.9	11
38	Medicine. Placebo-controls in short-term clinical trials of hypertension. <i>Science</i> , 2001 , 292, 2013-5	33.3	27
37	Patients who want their family and physician to make resuscitation decisions for them: observations from SUPPORT and HELP. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Hospitalized Elderly Longitudinal Project. <i>Journal of the American Geriatrics Society</i> , 2000 , 48, S84-90	5.6	138
36	Physician understanding of patient resuscitation preferences: insights and clinical implications. <i>Journal of the American Geriatrics Society</i> , 2000 , 48, S44-51	5.6	85
35	Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. <i>Circulation</i> , 2000 , 102, 1375-81	16.7	48
34	Cigarette smoking: how much worse can it get?. <i>Circulation</i> , 2000 , 102, 1340-1	16.7	4
33	Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. <i>Circulation</i> , 2000 , 101, 751-7	16.7	92
32	Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. <i>Circulation</i> , 2000 , 101, 2682-9	16.7	94
31	Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. <i>Circulation</i> , 2000 , 101, 366-71	16.7	89
30	Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. <i>Circulation</i> , 2000 , 101, 2231-8	16.7	114
29	Evaluating the potential economic attractiveness of new therapies in patients with non-ST elevation acute coronary syndrome. <i>Pharmacoeconomics</i> , 2000 , 17, 263-72	4.4	6
28	Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. <i>Circulation</i> , 1999 , 100, 2045-8	16.7	246
27	Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. <i>Circulation</i> , 1999 , 99, 1951-8	16.7	127
26	Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. <i>Circulation</i> , 1999 , 100, 14-20	16.7	462
25	Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. <i>Circulation</i> , 1999 , 100, 2067-73	16.7	173
24	The GUSTO Trials. <i>Journal of Interventional Cardiology</i> , 1999 , 12, 13-31	1.8	1
23	New Agents, New Trials, New Solutions. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 5, S151-S159	5.1	
22	Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 2651-63	1.6	34

21	Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. <i>Circulation</i> , 1998 , 97, 1702-7	16.7	147
20	Outcomes of Diabetic Patients Following Acute Myocardial Infarction: A Review of the Major Thrombolytic Trials. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1997 , 4, 100-111		
19	Surrogate and physician understanding of patients' preferences for living permanently in a nursing home. <i>Journal of the American Geriatrics Society</i> , 1997 , 45, 818-24	5.6	126
18	Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 415-423	5.1	1
17	Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. <i>Circulation</i> , 1997 , 96, 122-7	16.7	139
16	Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. <i>Circulation</i> , 1997 , 96, 2551-6	16.7	173
15	Identifying Patient Risk: The Basis for Rational Discharge Planning After Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 1996 , 3, 107-115	5.1	4
14	Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. <i>Circulation</i> , 1996 , 94, 629-35	16.7	104
13	A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. <i>Circulation</i> , 1995 , 91, 1966-74	16.7	134
12	Atenolol reduced ischemia-related events in asymptomatic ischemia. <i>ACP Journal Club</i> , 1995 , 122, 32		
11	Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. <i>New England Journal of Medicine</i> , 1994 , 331, 1130-5	59.2	269
10	Early ischemia after thrombolytic therapy for a first myocardial infarction was associated with increased total cardiac events and emergency revascularization. <i>ACP Journal Club</i> , 1993 , 119, 82		
9	Thrombolytic therapy for acute myocardial infarction. A review. <i>Drugs</i> , 1992 , 44, 293-325	12.1	114
8	Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis. <i>Thrombosis and Haemostasis</i> , 1992 , 67, 292-296	7	33
7	Intravenous Heparin, Thrombolytics, and Medical Marketing. <i>Journal of Interventional Cardiology</i> , 1991 , 4, 1-4	1.8	6
6	Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 1991 , 65, 275-279	7	42
5	Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute myocardial infarction. TAMI Study Group. <i>Catheterization and Cardiovascular Diagnosis</i> , 1990 , 20, 221-6		5
4	Current management of mitral valve incompetence associated with coronary artery disease. <i>Journal of Cardiac Surgery</i> , 1989 , 4, 25-42	1.3	17

- 3 Regression modelling strategies for improved prognostic prediction. *Statistics in Medicine*, **1984**, 3, 143-52, 1208
- 2 Tying clinical research to patient care by use of an observational database. *Statistics in Medicine*, **1984**, 3, 375-87, 23, 59
- 1 A View from Academia67-76